Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  linifanib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-13 of 13 for your search:
Start Over
Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M06-882, NCT00486538
Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M06-880, 2007-005245-37, NCT00517790
Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M06-879, NCT00517920
Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-265, 2007-005905-23, NCT00645177
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-300, 2007-007081-38, NCT00707889
Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-301, 2007-007107-32, NCT00716534
A Phase 1 Study of ABT-869 in Subjects With Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-227, NCT00718380
Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-384, NCT00733187
A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M11-306, NCT01114191
A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: W12-076, NCT01225302
To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M11-817, NCT01381341
Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M11-307, NCT01401933
An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M12-749, NCT01413893
Start Over